Thursday, July 30, 2026 — Field Note
A deeper look at one story shaping medical device and health tech.
FIELD NOTE
A Rebate Is Not a Recovery
Three of the largest device makers in the world reported second-quarter results in the last 48 hours, and all three booked money back from the U.S. government.
GE HealthCare recognized $129 million in International Emergency Economic Powers Act tariff refunds, lifting net income to $561 million from $486 million a year earlier. Philips booked €186 million, roughly 4.2 percentage points of its 16.4% adjusted EBITA margin. Boston Scientific recognized about $80 million in cost of products sold, which CFO John Monson told analysts represents substantially all of what the company expects to receive.
The money traces back to February 20, when the Supreme Court held 6–3 that IEEPA does not authorize the president to impose tariffs. The Court of International Trade subsequently ordered Customs and Border Protection to refund approximately $165 billion in duties collected across more than 53 million entries, and directed CBP to build an automated system to process them. Treasury Secretary Scott Bessent called the prospect “the ultimate corporate welfare” and predicted years of litigation. The checks cleared in about five months.
What matters for operators is not that the money arrived. It is what each company did with it in the disclosure.
GE HealthCare drew the sharpest line. Of the $129 million, the company excluded $106 million — the portion relating to 2025 duties — from adjusted figures entirely, keeping only $23 million, about four cents a share, in adjusted results. Then it reaffirmed full-year guidance without change. The underlying quarter carried its own weight: organic orders up 11.1%, backlog at a record $23.9 billion, book-to-bill of 1.15. Shares rose roughly 12% premarket.
Philips took the opposite approach and raised guidance on the strength of the refund, lifting its full-year adjusted EBITA margin target to 13.5%–14.0% from 12.5%–13.0% and free cash flow to €1.5–1.7 billion. The company acknowledged that without the one-time benefit, underlying profitability would have declined slightly on cost inflation. Investors noticed. The stock fell 9% Tuesday to its lowest level in a year, pressured further by new Chinese rules routing public hospital device purchases through a centralized state program.
Boston Scientific presented the cleanest illustration of the gap between the two numbers. Organic revenue grew 7%, at the high end of guidance. Adjusted EPS of $0.86 beat the range. And the company still cut its full-year organic growth outlook to 5%–6%, citing a slowdown in Watchman and competitive pressure in U.S. electrophysiology, while announcing a restructuring targeting roughly $500 million in run-rate savings by the end of 2029. The refund landed in the same quarter as a decision to take out half a billion dollars of cost.
The through-line: a tariff refund is a balance-sheet event that arrives dressed as an operating one. It flows through cost of goods or income from operations, it expands margin, and it does so with no relationship whatsoever to whether the underlying business improved. Every finance team in the industry now has one quarter in which the reported margin and the earned margin diverge, and a decision to make about how visible to render the difference.
The second point is more durable. The refunds close out a tariff regime that no longer exists — but the tariffs do. Within a day of the February ruling, the administration moved to replace the invalidated levies with a 10% across-the-board tariff under Section 122 of the Trade Act of 1974, and new duties covering 60 trading partners took effect this month. Philips said plainly that elevated tariff costs continue to pressure operations. GE HealthCare cited geopolitical instability weighing on costs, supply chains, and logistics.
So the industry got its money back for duties paid under a statute the Court rejected, and is now paying comparable duties under statutes it hasn’t. The refund is not relief. It is a reconciliation of one legal theory, arriving in the middle of a cost structure that hasn’t changed.
For anyone building a 2027 plan on the back of this quarter’s margin, the useful question is which number the board is going to remember — the one that includes the refund, or the one that shows what the business actually did.
SPONSORED BY RŌG HEALTH
Where does your commercialization actually stand?
Two minutes to find out.
Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.